Inhibikase Therapeutics completed the acquisition of CorHepta Pharmaceuticals for $14.8m.

Synopsis

Inhibikase Therapeutics, a company specializing in kinase inhibitor therapeutics, completed the acquisition of CorHepta Pharmaceuticals, a company focused on cardiovascular therapies, for $14.8m.

Principals

target

Corhepta Pharmaceuticals

bidder

Inhibikase Therapeutics

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

Market Context